-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis Group announced today that Remibutinib's phase III trial of REMODEL-1/-2 for relapsing multiple sclerosis has achieved positive top-line results. Remibutinib is a highly selective and highly effective oral Bruton tyrosine kinase inhibitor; compared with teriflunomide, it shows excellent efficacy in reducing the annual recurrence rate and inflammatory brain lesions, and also has good safety characteristics. The results of the REMODEL trial showed that in two phase III trials for adults with recurrent multiple sclerosis, remibutinib significantly reduced the annualized recurrence rate.

Zhitongcaijing·09/02/2026 11:17:07
Listen to the news
Novartis Group announced today that Remibutinib's phase III trial of REMODEL-1/-2 for relapsing multiple sclerosis has achieved positive top-line results. Remibutinib is a highly selective and highly effective oral Bruton tyrosine kinase inhibitor; compared with teriflunomide, it shows excellent efficacy in reducing the annual recurrence rate and inflammatory brain lesions, and also has good safety characteristics. The results of the REMODEL trial showed that in two phase III trials for adults with recurrent multiple sclerosis, remibutinib significantly reduced the annualized recurrence rate.